News ReleaseView printer-friendly version << Back
AcelRx Pharmaceuticals Reports Publication Analyzing Errors Associated with Existing IV Patient-Controlled Analgesia Systems
"The use of existing IV patient-controlled analgesia systems often results in adverse drug- and device-related events which can cause serious complications for patients," commented Dr.
Details on the publications:
Mohanty M, Lawal O, Skeer M, Lanier R, Erpelding N, Katz N. Medication Errors Involving Intravenous Patient-Controlled Analgesia: Results from the 2005–2015 MEDMARX Database. Therapeutic Advances in Drug Safety. 2018 April.
Lawal O, Mohanty M, Elder H, Skeer M, Erpelding N, Lanier R, Katz N. The nature, magnitude, and reporting compliance of device-related events for intravenous patient-controlled analgesia in the FDA Manufacturer and User Facility Device Experience (MAUDE) database. Expert Opinion on Drug Safety. 2018 February.
About the Journals:
Therapeutic Advances in Drug Safety delivers the highest quality peer-reviewed articles, reviews, and scholarly comment on pioneering efforts and innovative studies pertaining to the safe use of drugs in patients. The journal has a strong clinical and pharmacological focus and is aimed at clinicians and researchers in drug safety, providing a forum in print and online for publishing the highest quality articles in this area.
Expert Opinion on Drug Safety is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles on all aspects of drug safety and original papers on the clinical implications of drug treatment safety issues, providing expert opinion on the scope for future development.
For additional information about AcelRx's clinical programs, please visit www.acelrx.com.
View original content with multimedia:http://www.prnewswire.com/news-releases/acelrx-pharmaceuticals-reports-publication-analyzing-errors-associated-with-existing-iv-patient-controlled-analgesia-systems-300638490.html
Brian Korb, Solebury Trout, 646-378-2923, email@example.com, or Raffi Asadorian, Chief Financial Officer, AcelRx, firstname.lastname@example.org